Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Dezima's objective is to develop compounds from pre-clinical development to meaningful proof of concept (PoC) in patients.
Phone: +31 35 699 30 00
Gooimeer 2 - 35
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)